Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02931253 · ClinicalTrials.gov registry record · Phase 2

Metformin as an Upstream Therapy in Atrial Fibrillation

A Phase 2 study, sponsored by The Guthrie Clinic.

Terminated
Registry status
Phase 2
Development phase
6
Enrollment target

NCT02931253: Clinical Trial Phase 2 study, sponsored by The Guthrie Clinic.

NCT02931253 is a Phase 2 study that was terminated before completion, run by The Guthrie Clinic. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02931253, a Phase 2 study, was terminated before completion, sponsored by The Guthrie Clinic.

TERMINATED
Registry status
Phase 2
Development phase
6 participants
Enrollment target

Study Summary

The purpose of this study is to see if the study drug metformin will help patients who are overweight and have atrial fibrillation. This study aims to see if metformin helps patients stay in normal sinus rhythm after a catheter ablation. Metformin is investigational for use in patients with atrial fibrillation. Metformin is approved by the Food and Drug Administration (FDA) for use in patients with type 2 Diabetes Mellitus. Metformin is used with a proper diet and exercise program to control high blood sugar, and has been shown to help people lose weight. This study aims to look at the effects of metformin on weight loss and heart rhythm in patients with atrial fibrillation.

Primary Outcome

Number of participants who maintain sinus rhythm, normal heart rhythm by electrocardiogram (ECG)

Interventions

  • DRUG Metformin

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2017-04-11
Est. Completion 2018-07-10
Phase Phase 2
The Guthrie Clinic

17 total trials

Why NCT02931253 stopped before completion

NCT02931253 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 1 intervention - of which Metformin is the first listed.

NCT02931253 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02931253 about?

NCT02931253 is a clinical study titled "Metformin as an Upstream Therapy in Atrial Fibrillation". The purpose of this study is to see if the study drug metformin will help patients who are overweight and have atrial fibrillation. This study aims to see if metformin helps patients stay in normal sinus rhythm after a catheter ablation. Metformin is investigational for use in patients with atrial ...

What is the current status of trial NCT02931253?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2017-04-11. Estimated completion is 2018-07-10.

What interventions are being tested in trial NCT02931253?

The interventions under investigation include: Metformin (DRUG).

Who is sponsoring clinical trial NCT02931253?

This trial is sponsored by The Guthrie Clinic, which has 17 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02931253's enrollment target sits among peer trials

6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02931253, the US trial registry maintained by the National Library of Medicine. NCT02931253 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.